Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Two Former Ariad Directors Charged With Insider Trading June 27, 2017 Why Celgene Gets No R-E-S-P-E-C-T, But Should June 12, 2017 Why Pfizer Could and Should Scoop Up Celgene in 2018 December 4, 2017
